SciFounders

Luminate Medical is focused on developing a medical device aimed at preventing hair loss during chemotherapy. Recognizing the significance of hair for personal identity and self-esteem, the company has created a portable and comfortable wearable system. This innovative device allows patients to manage and mitigate the side effects associated with cancer treatment, thereby helping them maintain their confidence and dignity during a challenging time. By leveraging advances in medical technology, Luminate Medical is dedicated to enhancing the quality of life for individuals undergoing chemotherapy.

ImmTune Therapies specializes in developing a cell and gene therapy platform that simplifies complex biomanufacturing processes. The company focuses on CAR-T-based cell and immune therapies for cancer treatment, designing vectors that facilitate the delivery of chimeric antigen receptors (CARs) to T-cells within the body. This innovative approach aims to enhance the safety and efficiency of delivering therapies directly to tumor cells, enabling clinicians to administer treatments more effectively. By streamlining the production and application of cell therapies, ImmTune Therapies seeks to reduce the costs associated with treatment, making these advanced therapies more accessible to patients.

Engage Bio is developing mRNA treatments that change cancer cells into production facilities for immunotherapies. With the help of these treatments, the immune system is activated and directed toward the tumour.

Inherent Targeting develops fluorescent contrast agents that target nerves to improve surgical outcomes. The company was founded in 2019 and is headquartered in Portland, Oregon.

ImmTune Therapies specializes in developing a cell and gene therapy platform that simplifies complex biomanufacturing processes. The company focuses on CAR-T-based cell and immune therapies for cancer treatment, designing vectors that facilitate the delivery of chimeric antigen receptors (CARs) to T-cells within the body. This innovative approach aims to enhance the safety and efficiency of delivering therapies directly to tumor cells, enabling clinicians to administer treatments more effectively. By streamlining the production and application of cell therapies, ImmTune Therapies seeks to reduce the costs associated with treatment, making these advanced therapies more accessible to patients.

Current Surgical is a surgical device company that develops precise tools for the treatment of solid tumors. The company was founded in 2020 and has its headquarters in Washington, DC.